We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 15, 2022

Efficacy of Ciltacabtagene Autoleucel in Chinese Patients With Relapsed/Refractory Multiple Myeloma

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)
J. Clin. Oncol 2022 Oct 21;[EPub Ahead of Print], JQ Mi, W Zhao, H Jing, W Fu, J Hu, L Chen, Y Zhang, D Yao, D Chen, JM Schecter, F Yang, X Tian, H Sun, SH Zhuang, J Ren, X Fan, J Jin, T Niu, SJ Chen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading